One of the largest compounders in the U.S., Hims & Hers, is spending millions of dollars to run a misleading Super Bowl ad that misrepresents their unapproved GLP-1 medicines.
The ad runs afoul of the Federal Food, Drug, and Cosmetic Act (FDCA), which requires that advertising for prescription drugs—including compounded drugs–not be false or misleading.
It also resurfaces serious concerns about the lack of oversight of the compounding industry, specifically that these products don’t undergo the same extensive FDA review for safety and effectiveness. At the same time, the way these products are advertised and marketed violates the stringent requirements imposed on advertising for all products.
Here are a few examples of how the Hims & Hers ad is misleading, deceptive and misbrands their unapproved products.
-
The ad entirely omits risk information, failing to provide fair balance. The ad doesn’t include any information about the risks and side effects associated with the compounded GLP-1 drugs displayed in the commercial and marketed across the Hims & Hers platforms. The ad shows vials and pills, which appear to be the compounded GLP-1 products offered on Hims & Hers website, and includes benefit claims, describing the products as “life changing weight-loss medications” and “doctor-trusted.” However, the ad does not include any safety or risk information to balance the benefit claims, which presents a misleading impression that unapproved compounded GLP-1 drug products are safe and effective. This is especially problematic because the FDA has warned that compounded products pose a higher risk to patient safety than FDA-approved medicines.
-
The ad claims Hims & Hers compounded GLP-1 drugs are safe and effective without any evidence. Compounded drugs don’t go through the rigorous FDA review process to evaluate their safety, effectiveness and quality. For Hims & Hers compounded GLP-1s, no major clinical studies have been reported to substantiate their safety or efficacy. Yet, the ad includes claims that falsely imply that their unapproved compounded drug products have been demonstrated to be safe and effective. Absent data, these claims are unsubstantiated, misleading and deceptive.
-
The ad fails to clearly and prominently disclose that the FDA has not approved or evaluated these products for safety, effectiveness, or quality. The ad does contain a brief disclosure that compounded drugs are not FDA-approved or evaluated for safety, effectiveness, or quality, but the text is too small and can be easily missed by the viewer. As a result, patients may be misled into believing that the products promoted in the ad are FDA-approved or reviewed by FDA for safety, effectiveness or quality. FDA requires text in pharmaceutical ads to be easy to read for consumers. For example, in recent guidance interpreting its regulations around presentation of risk information in television advertising, the agency outlined detailed recommendations to help ensure that textual information is “easily readable.”
The compounding industry’s trade association, which Hims & Hers is a member, recently released guidelines for how the compounding industry should and shouldn’t market their products. These guidelines clearly acknowledge that unless drugs are FDA approved for a particular use, they “cannot be promoted as safe and effective for treating that condition. This holds true for compounded medications…”
It’s worth noting that the Hims & Hers ad does virtually everything the trade association says compounders shouldn’t do to avoid “risk of action being taken against them” by regulators.
Compounders are subverting the FDA’s rigorous approval process while increasing the risk for patient safety and misleading the public, without accountability for running false and misleading ads like these.
We urge federal and state regulators to conduct real oversight over compounders, including by ensuring that their advertising and promotion does not mislead patients or put them at increased risk.
Nick McGee
Nick McGee is deputy vice president, public affairs, at PhRMA focusing on communications strategies and activities for the organization’s advocacy priorities.
Nick McGee
Mass compounding puts patients at risk
Advancing patient care: A look at new medicines approved in 2025
Knockoffs of FDA-approved drugs put patients at risk
PDUFA: Essential to America’s edge in drug development and patient access
More oversight needed of unapproved medicines that threaten patients’ health
The use of real-world data in drug development
New analysis: Accelerated approval pathway is changing lives in underserved communities
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
Florida’s importation plan puts patients in danger
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
Decentralized clinical trials and the future of drug development
How FDA’s modernization strategy could improve drug development
Setting the record straight on accelerated approval
FDA should remain the authority on the safety and effectiveness of medicines
What you should know about real-world evidence and drug development
Three things to know about the accelerated approval pathway
PDUFA and BsUFA reauthorizations are wins for patients
Word of the Month: Biomarkers and surrogate endpoints
Ensuring timely reauthorization of PDUFA and BsUFA
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
The importance of timely PDUFA and BsUFA reauthorization
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition
Meeting Tomorrow: Looking ahead to PDUFA VII
The impact of monoclonal antibodies and COVID-19 recovery
PDUFA VII is critical for future biopharmaceutical innovation and for patients
How strengthening the biosimilar marketplace benefits patients
The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Nearly 400 cell and gene therapies in development to target a broad range of diseases
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Guest Post: Using the patient voice to go boldly
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
Guest post: Hearing from patients on Rare Disease Day
Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation
Why state drug importation pilot programs don’t work
Putting 2018 medicine approvals in context
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
Balancing innovation and competition in the biologics marketplace
New analysis shows that more medicines worldwide are available to U.S. patients
Spending on medicines grew less than one percent in 2017
Rare Disease Day: Unmet need inspires innovation
Innovation comes in many forms, including new and expanded uses of existing medicines
ICYMI: Why 2017 medicine approvals matter
New surveys find payers and providers want more data from biopharmaceutical companies
Supporting opportunities for enhanced competition in the marketplace
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Opportunities to build upon enhanced competition for medicines in the marketplace
Why reauthorization of PDUFA matters
A critical opportunity to prevent prescription drug abuse
Guest Post: The importance of a modern FDA in drug discovery
HimsHers ad
FDA
Major drug compounder is spending millions on misleading Super Bowl ad
HimsHers ad